Currently, more LAG-3 immune checkpoint inhibitors (including tebotelimab, relatlimab, IMP321, etc.)have been trialed and presented strong efficacy against solid tumors including melanoma, breast cancer, NSCLC, and gastric cancer [79,80,81,82,83]. Here, LAG3 is linked to breast carcinoma.